Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib vs Imatinib in GIST
NCT00372567Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2007
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of sunitinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by Pfizer. Primary endpoint: Progression-Free Survival. Started Jun 2007; status: terminated.
02
Drugs
sunitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00372567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372567.